New Partnership between Gladstone Institutes and CZ Biohub

Gladstone Institutes and the Chan Zuckerberg Biohub signed an affiliation agreement to increase their research collaboration. The two San Francisco organizations, both located in the Mission Bay neighborhood known for being a hub for health and biotech, will partner to uncover the fundamental mechanisms of disease in order to find new prevention strategies, treatments, and cures.

“For decades, Gladstone has distinguished itself as a top biomedical research institution, and Biohub scientists have regularly collaborated with Gladstone’s talented researchers,” says Joe DeRisi, PhD, CZ Biohub president. “This new affiliation will make these exchanges even more robust and productive.”

Leaders from Gladstone and CZ Biohub join forces to accelerate the pace of discoveries. From left to right: Robert Obana, Mandana Asgharnejad, Joe DeRisi, and Deepak Srivastava.

Gladstone researchers are eligible to apply to become CZ Biohub Investigators, and as part of the new agreement, those selected can use Biohub’s funding to support their research both at Gladstone’s and Biohub’s scientific facilities.

“Both Gladstone and Biohub are focused on supporting the boldest and riskiest ideas, knowing these will lead to the most disruptive solutions to overcome unsolved diseases,” says Deepak Srivastava, MD, president of Gladstone. “It’s exciting to join forces so we can achieve our common missions.”

Combining Skills and Resources

The new affiliation agreement enables Gladstone investigators who are appointed as CZ Biohub Investigators to have access to resources to participate in research at both organizations. These investigators can also hire postdoctoral fellows and staff to work at the Biohub’s facilities to support their science.

Current Chan Zuckerberg Biohub Investigators at Gladstone include virologist Melanie Ott, MD, PhD; data scientist Katie Pollard, PhD; and bioengineer Seth Shipman, PhD.

“CZ Biohub is known for being exceptionally collaborative, which is a value we share at Gladstone,” says Gladstone Chief Operating Officer, Robert Obana, MBA. “By combining our unique strengths, I believe we will successfully accelerate the pace of our discoveries and help make a substantive impact on medicine and healthcare through our research.”